scPharmaceuticals Inc. (SCPH)

Market Cap	150.60M
Revenue (ttm)	36.33M
Net Income (ttm)	-85.15M
Shares Out	50.28M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	193,959
Open	3.110
Previous Close	3.130
Day's Range	2.990 - 3.132
52-Week Range	2.750 - 5.650
Beta	0.39
Analysts	Strong Buy
Price Target	14.00 (+367.45%)
Earnings Date	Mar 19, 2025

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company’s lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consistin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 17, 2017
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: SCPH
• Website: https://www.scpharmaceuticals.com

Financial Performance

In 2024, scPharmaceuticals's revenue was $36.33 million, an increase of 167.28% compared to the previous year's $13.59 million. Losses were -$85.15 million, 55.4% more than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for SCPH stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 367.45% from the latest price.

Price Target

$14.0

(367.45% upside)

Analyst Consensus: Strong Buy